quarter year which XX Health non-proprietary from has fadraciclib treated Thank to-date exceeded were year for CYCXXXX. business enrollment made in World XXXX everyone, sponsored the in excellent total We our new you, XX our patients fourth and for the joining XXXX and studies Jan, update of over thank and full full you, the quarter as for today international call. Organization us progress name with company
understanding of the biology patients. of at cycle the life into vision cancer can that translate improve Cyclacel control is Our medicines
suppress transcriptional into to response resistant to to cancer use develop in strategy order and science regulation ability insights discover to pathways can damage cells and Our is the that of DNA drugs treatments. become novel
demonstrating Our realize of business strategy efficacy value our to and effectiveness assets. pipeline safety, stockholder cost is by
which addicted, is amplification as susceptible Over expression of of MCLX to and to transcription or cancer such proteins cells pharmaceutical respectively proteins, increases survival they become resistant Cyclin are or inhibit oncoproteins Cyclacel or cells. of meaning that intervention. rate cancer strategy therapeutic E of such label the cancer to growth
address resistance pathway. pipeline Fadraciclib targeting medicines act novel by which We to through of problem of of components believe isoforms positioned precision the that pXX innovative cancer medicine a led CDKX CDKX and our CDK the is key strategy. the inhibitor well fadraciclib as a is
evaluating Mcl-X cells in is protein and gain cancer confer treatments. member over and therapy malignancies. cancer BCLX against survive amplification. alternately resistance Cyclin is solid X family. advantage in an anti-cancer agent CDKX hematological Phase results BCLX help of with a Mcl-X proteins in of reducing the a normal cells Cyclacel Activity as to and survival cancer single and E tumors patients a CDKX in again suppression fadraciclib combination in
that suppressing of bring anti We Mcl-X scientific patient doses durable cancer strategy intensely is in demonstrated race And in solid believe a in tolerable tumors. attention of lot market in pharmaceutical as progress and The the fadraciclib leader suppression that communities. Cyclacel has has at to is attracted competitive because race, with monotherapy this a activity drugs Mcl-X. of to suppress and Mcl-X
as XX our in study this a observed majority of study part single were which of Mcl-X recorded dose part In of three the at patients previously every patients, one escalation administered four a enrolled the meter These schedule. in hour results weeks. intravenous XXX-XX fadraciclib of sparsely milligrams XXX was given recommended does phase using administration enrolled squared the X
more patients schedule. escalation enrolled the days XX a part in is one, every two fourth a weeks. with and study have at of part infusion one nine, three further reached two, In ongoing dosing milligrams eight in given two this flat dose. Dose on XXX by frequent has the hour level We part, fadraciclib the
achieved cancer of On a our two amplified shrinkage with third fadraciclib with of XXX response pretreated excited partial that XX%. stable After monotherapy were heavily quarter to report Mcl-X this tumor cycles call, PR. we a milligrams patient endometrial achieved or patient disease had
In same reached XX%. four the shrinkage had target confirmatory lesions on cycles the after tumor scan, dose of her
XX patient is that at the We the after the recently tumor assessed to are same the XX%. investigators study on continuing have on pleased cycles report and dose shrinkage
with We and also of two milligrams, that and treated shrinkage at tumor and assessments, of XXX fadraciclib cancer achieved XX%. second was four a stable ovarian also cycles after patient was disease shrinkage had XX% investigator assessed amplification a secondly reported per cycles tumor monotherapy
suppress schedule to historical strategy lived such for is be Mcl-X may This dosing with of contrast or fast E. frequent experience a a the inhibitors to previously that reported as Mcl-X. suggest fadraciclib suppress findings short Cyclin and in CDK transcripts These preferred transiently
capsules. have after milligrams as flat Flavopiridol, infusion, our two administered formulations two using dose begun by first as part continuous the known mouth example, hours XX treating patients X Alvocidib reached lasting loading level In a hours, or And and as strategy. was parallel, at given three dose. For either fadraciclib also XX we of XXX
the a fadraciclib PK in encouraging with two Pharmacokinetic predictable patients by oral levels. capsules or exposure data closely the PK overlapping profile achieved early administration demonstrated
oral updated ID the form plan to for and efficacy initial report safety data mechanistic We this with form. for year later safety, data NPK along the
combination it line an with antibody. is first advance, approved with Cyclacel now Let In for anti-CDXX or Venetoclax potential BCLX. demonstrated fadraciclib venetoclax. therapeutic have suppressing MCLX alone with an demonstrated synergy CLL malignancies. both by patient authors for BCLX and and or fadraciclib turn a of Preclinical synergistic combinations, important in is hematological inhibitor preclinical studies in second data particular, either data to external us are scientists
for patients and amplification. responding chemotherapy, line unfit agents recently, first this and for methylating is approval AML, granted often combination stop Venetoclax analogue. More in with a correlated MCLX eventually with accelerated Venetoclax hypo nucleoside or FDA treated
have opened studies can that’s refractory two the in activity BCLX result relapsed both hypothesis leukemias. We anti-cancer test escalation or to and MCLX against dose suppressing
medical and XXX-XX. the in relapsed evaluating We fadraciclib relapsed patients relapsed the remains venetoclax or developments or approval with or or recent XXX-XX are venetoclax refractory and an combination the in AML. study specifically refractory AML, in in in refractory AML CLL MDS, accelerated unmet need including Despite
none care of relapsed previous previous IO agents A multiple with X associated our which with X AML to or when present patients one therapy. historical large investigational Unlike present sapacitabine or combinations, experience patients would or are refractory line currently including Today's facilities. investigational number immuno-oncology Phase of tertiary at are with X centers. evaluation lines, in with AML
Of with our preceded performance comorbidity. Consequently, of expectations or anti in of prognosis, associated patients. scores in of flavopiridol venetoclax risk this about at in syndrome Leukemia X%. strong and lower leukemia with TLS XX% populations TLS poor activity license with is heavily low treatment leukemia are note about modest tumor is
them. results increasing gum levels cancer rapid the number can acid of a remove and circulation, potassium large TLS death of before license uric up cells kidneys which from and
may active the drug that well that management preferable. too TLS is of the from works to be treatment evidence against and a For hydration TLS effects leukemia hemodialysis. ranges shorter
hour rapidly which four XXX-XX primary doses AML Reflecting alternative weeks. need dose receive treatments, fadraciclib enrolled of have on X fusion endpoints the a every once phase of Heavily determination of XX patients in a the and venetoclax pretreated we unmet combination escalating of is safety. two oral patients for recommended and schedule,
mechanisms. two patients meter We milligrams follows blasts related in lower a previously per reported have now anti-leukemia square, to with equivalent peripheral on five the fadraciclib. with escalated in with consistent reductions of the XXX reported level leukemic of This patients combination. was patients to doses treated approximately drugs flat TLS both XXX to where activity blood dose for dose milligrams of XXX
synergy beneficial fadraciclib and suppressing protein evidence Based the patients. alone. clinical plan suggesting schedule and flat by both disease PR in on stable more the findings, supported tumor leukemia of associated hour patients, may suppression also also hits than venetoclax and is Mcl-X solid in study these XXX either The double to that apoptosis, rationale dose in with inducing milligrams confirming for the we AML Bcl-X evaluate one be that of
Mcl-X plays leukemia CLL role. In dominant By especially causing the feature. eventual cells, often over CLL main the In is contrast nodes, a expression. AML, expression stop in is relapse, lymph associated Bcl-X the Mcl-X in venetoclax, over with which to responding
MRD and an minimal achieving for nodes or fadraciclib disease of by treatment residual is the therefore and a disease CLL. venetoclax strategy combination negativity Eradicating attractive in lymph
relapse first the free refractory a enrollment CLL, line has In therapies. study periods the XXX-XX long or after survival of been slow, reflecting relapsed
after need will relapse, patient a a that Cyclacel relapse. large persist medical have Given of emerging as unmet to number eventually investigators advised is
help the rates. increase To enrollment
MD addition in amendments, per dose implemented certain far have We to been squares. to sites. level additional Anderson, in open and new protocol meter XX are so X discussions milligrams patients two treated have Three up with or sites
cycles tolerated. are XX fadraciclib weeks squared respectively, well received ibrutinib six at was every and of two for failed patients dosed and which therapy once combination The first and the four venetoclax meter milligrams two per
part refractory them MDS with relapsed patients and patients experienced therapy. a safety damage with Both an two the as In with a effectiveness frontline nucleoside sapacitabine sapacitabine, node in Phase approval oral achieving analog the The venetoclax enrolling combination nucleoside of our lymph of negative we're MRD or one hyperventilating evaluating of our accelerated study program X/X response reduction size is study XXX-XX of This or clinical mirrors design status. DNA in agents with with or study. of analog venetoclax. AML intravenous
with therapy refractory MDS is Hematology protocol frontline remissions support venetoclax combination relapsed with dosed or agents. and in to sapacitabine venetoclax Congress published such hypomethylating therapy relapsed effective Based oral cytarabine of orally. where complete the both regimen are our sapacitabine active failed patients at is induces evaluating sapacitabine as XXth, an combination data and or refactory Bcl-X therefore who we inhibitors Preclinical in Combining AML. in AML European on treatment and clinical patients investigations have prior but offer and However, prior the drugs Association approved. for may already disease, as
our dose limiting clinical the Four patients was In with PLKX leukemias agent house. been observed XXX-XX, esclation thus in which fadraciclib discovered to been recruited human, antimycotic No our CYCXXX, single program third toxicities in we're like polo-like-kinase far. dose inhibitor, study. have evaluating have first advanced or
demonstrated target inhibition CYCXXX xenograft human in of is PLKX selective selective small and activity high models cancers. inhibitor molecule a that in potent
pursuing MCLX fadraciclib We cancer as the are believe in in particular, medicine monotherapy data in a that establishing company's position overcome collected precision with We of support to-date resistance leadership suppressions. combinations. the and clinical totality approach achievements a proud of and XXXX to in
strategy As we our clinical development in programs. executing our continue advancing
X safety, for fadraciclib. in and or proof-of-concept dosing Phase refectory patients updated Our schedule X data the relapsed and patients safety report upcoming AML report decay efficacy sapacitabine-venetoclax advance key from from frequent with MDS. in IV data fadraciclib Phase studies initial CLL, initial and milestones MDS solid include with Utilizing Phase relapsed Xb/X venetoclax a data Report study in refractory AML cancers.
Report of in patients metastatic with first Xb/X initial XXXX. CYCXXX Phase relapse the on the report for reported With investigators. refectory data the sapacitabine when estimated in leukemia first IST BRCA X from hand mutant quarter study cancer in combination human from of breast data by Phase the capital and olaparib
milestones We have clinical studies. key clinical to us take to ongoing our the resources in
financials. our like Paul Paul? XXXX to I to over review full turn would to the year fourth call quarter and now
